Cogent Biosciences (COGT) Net Income towards Common Stockholders (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$111.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 54.48% year-over-year to -$111.2 million in Q1 2026; TTM through Mar 2026 was -$382.5 million, a 43.08% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 billion, down 126.83% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$111.2 million, down from -$110.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for COGT reached as high as -$35.9 million in Q1 2022 and fell as low as -$111.2 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$65.9 million across 5 years, with a median of -$62.8 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders tumbled 243.33% in 2022 and jumped 36.61% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$40.0 million in 2022, then slumped by 47.54% to -$59.0 million in 2023, then grew by 4.57% to -$56.3 million in 2024, then tumbled by 95.57% to -$110.1 million in 2025, then fell by 1.01% to -$111.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$111.2 million in Q1 2026, -$110.1 million in Q4 2025, and -$85.2 million in Q3 2025.